Incannex Healthcare (IXHL) Common Equity (2020 - 2026)
Incannex Healthcare (IXHL) posted Common Equity of $75.2 million for Q1 2026, up 2.49% sequentially from $73.4 million in Q4 2025, and up 916.26% YoY from $7.4 million in Q1 2025.
Incannex Healthcare (IXHL) Common Equity (2020 - 2026) Analysis & Trends
Incannex Healthcare has reported Common Equity for 7 years, with the latest figure at $75.2 million in Q1 2026.
- Quarterly Common Equity rose 916.26% year-over-year to $75.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $75.2 million (up 916.26% YoY) and the FY2025 annual result came in at $13.4 million, up 19.36% from the prior year.
- Common Equity climbed to $75.2 million in Q1 2026 per IXHL's latest filing, from $73.4 million in the prior quarter.
- Over five years, Common Equity peaked at $77.0 million in Q3 2025 and troughed at $964000.0 in Q4 2024.
- A 5-year average of $27.7 million and a median of $19.8 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity slumped 94.89% in 2024, then surged 7514.73% in 2025.
- Over 5 years, Common Equity stood at $27.9 million in 2022, then tumbled by 32.39% to $18.9 million in 2023, then plunged by 94.89% to $964000.0 in 2024, then soared by 7514.73% to $73.4 million in 2025, then advanced by 2.49% to $75.2 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $75.2 million, $73.4 million, and $77.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 4.05 Bn |
| 10 | Incannex Healthcare | 41.61 Mn | 41.61 Mn | - | 75.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.23 Mn |
| Dec 31, 2025 | 73.41 Mn |
| Sep 30, 2025 | 77.01 Mn |
| Jun 30, 2025 | 13.39 Mn |
| Mar 31, 2025 | 7.40 Mn |
| Dec 31, 2024 | 964,000.00 |
| Sep 30, 2024 | 6.60 Mn |
| Jun 30, 2024 | 11.22 Mn |
| Mar 31, 2024 | 14.14 Mn |
| Dec 31, 2023 | 18.87 Mn |
| Sep 30, 2023 | 19.79 Mn |
| Jun 30, 2023 | 20.83 Mn |
| Mar 31, 2023 | 24.67 Mn |
| Dec 31, 2022 | 27.91 Mn |
| Jun 30, 2022 | 24.71 Mn |
| Jun 30, 2021 | 8.57 Mn |
| Jun 30, 2020 | 3.16 Mn |